Cargando…
Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas
Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326036/ https://www.ncbi.nlm.nih.gov/pubmed/35912165 http://dx.doi.org/10.2147/RRTM.S278135 |
_version_ | 1784757186461696000 |
---|---|
author | Suárez, Cristina Nolder, Debbie García-Mingo, Ana Moore, David A J Chiodini, Peter L |
author_facet | Suárez, Cristina Nolder, Debbie García-Mingo, Ana Moore, David A J Chiodini, Peter L |
author_sort | Suárez, Cristina |
collection | PubMed |
description | Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic cardiomyopathy and gastrointestinal disease. The infection is transmitted vertically and by blood/organ donation and can reactivate with immunosuppression. Case identification requires awareness and screening programmes targeting the population at risk (women in reproductive age, donors, immunocompromised patients). Treatment with benznidazole or nifurtimox is most effective in the acute phase and prevents progression to chronic phase when given to children. Treating women antenatally reduces but does not eliminate vertical transmission. Treatment is poorly tolerated, contraindicated during pregnancy, and has little effect modifying the disease in the chronic phase. Screening is easily performed with serology. Migration has brought the disease outside of the endemic countries, where the transmission continues vertically and via blood and tissue/organ donations. There are more than 32 million migrants from Latin America living in non-endemic countries. However, the infection is massively underdiagnosed in this setting due to the lack of awareness by patients, health authorities and professionals. Blood and tissue donation screening policies have significantly reduced transmission in endemic countries but are not universally established in the non-endemic setting. Antenatal screening is not commonly done. Other challenges include difficulties accessing and retaining patients in the healthcare system and lack of specific funding for the interventions. Any strategy must be accompanied by education and awareness campaigns directed to patients, professionals and policy makers. The involvement of patients and their communities is central and key for success and must be sought early and actively. This review proposes strategies to address challenges faced by non-endemic countries. |
format | Online Article Text |
id | pubmed-9326036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-93260362022-07-28 Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas Suárez, Cristina Nolder, Debbie García-Mingo, Ana Moore, David A J Chiodini, Peter L Res Rep Trop Med Review Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic cardiomyopathy and gastrointestinal disease. The infection is transmitted vertically and by blood/organ donation and can reactivate with immunosuppression. Case identification requires awareness and screening programmes targeting the population at risk (women in reproductive age, donors, immunocompromised patients). Treatment with benznidazole or nifurtimox is most effective in the acute phase and prevents progression to chronic phase when given to children. Treating women antenatally reduces but does not eliminate vertical transmission. Treatment is poorly tolerated, contraindicated during pregnancy, and has little effect modifying the disease in the chronic phase. Screening is easily performed with serology. Migration has brought the disease outside of the endemic countries, where the transmission continues vertically and via blood and tissue/organ donations. There are more than 32 million migrants from Latin America living in non-endemic countries. However, the infection is massively underdiagnosed in this setting due to the lack of awareness by patients, health authorities and professionals. Blood and tissue donation screening policies have significantly reduced transmission in endemic countries but are not universally established in the non-endemic setting. Antenatal screening is not commonly done. Other challenges include difficulties accessing and retaining patients in the healthcare system and lack of specific funding for the interventions. Any strategy must be accompanied by education and awareness campaigns directed to patients, professionals and policy makers. The involvement of patients and their communities is central and key for success and must be sought early and actively. This review proposes strategies to address challenges faced by non-endemic countries. Dove 2022-07-22 /pmc/articles/PMC9326036/ /pubmed/35912165 http://dx.doi.org/10.2147/RRTM.S278135 Text en © 2022 Suárez et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Suárez, Cristina Nolder, Debbie García-Mingo, Ana Moore, David A J Chiodini, Peter L Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas |
title | Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas |
title_full | Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas |
title_fullStr | Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas |
title_full_unstemmed | Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas |
title_short | Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas |
title_sort | diagnosis and clinical management of chagas disease: an increasing challenge in non-endemic areas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326036/ https://www.ncbi.nlm.nih.gov/pubmed/35912165 http://dx.doi.org/10.2147/RRTM.S278135 |
work_keys_str_mv | AT suarezcristina diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas AT nolderdebbie diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas AT garciamingoana diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas AT mooredavidaj diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas AT chiodinipeterl diagnosisandclinicalmanagementofchagasdiseaseanincreasingchallengeinnonendemicareas |